HC Wainwright reissued their buy rating on shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in a research note issued to investors on Friday.

A number of other analysts also recently commented on ACRX. Zacks Investment Research raised AcelRx Pharmaceuticals from a hold rating to a buy rating and set a $3.00 price objective on the stock in a research note on Wednesday, May 3rd. Jefferies Group LLC reissued a buy rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. ValuEngine raised AcelRx Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, July 24th. Piper Jaffray Companies set a $3.00 price objective on AcelRx Pharmaceuticals and gave the stock a hold rating in a research note on Tuesday, July 25th. Finally, Cowen and Company reissued a hold rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $7.57.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 4.50% during mid-day trading on Friday, reaching $2.90. The company’s stock had a trading volume of 1,242,263 shares. The company’s market capitalization is $131.60 million. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The firm has a 50 day moving average price of $2.65 and a 200-day moving average price of $2.77.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The firm had revenue of $2.66 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities analysts predict that AcelRx Pharmaceuticals will post ($1.18) EPS for the current fiscal year.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/05/acelrx-pharmaceuticals-inc-nasdaqacrx-receives-buy-rating-from-hc-wainwright.html.

In related news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of AcelRx Pharmaceuticals stock in a transaction on Monday, June 19th. The stock was sold at an average price of $2.40, for a total value of $2,100,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 28.10% of the company’s stock.

Several institutional investors have recently modified their holdings of ACRX. Teachers Advisors LLC boosted its position in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the last quarter. ING Groep NV boosted its position in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares during the last quarter. Finally, WealthTrust Axiom LLC boosted its position in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares during the last quarter. Institutional investors and hedge funds own 30.26% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.